BACKGROUND: The biology of malignant peritoneal mesothelioma (MPM) is largely unknown. In the present study, we assessed the expression of survivin and other members of the inhibitors of apoptosis proteins (IAP) family (IAP-1, IAP-2 and X-IAP) in a series of 32 MPM surgical specimens and investigated the effects of survivin knockdown in an established MPM cell line. METHODS: Expression of different IAPs was measured by immunohistochemistry. MPM cells were transfected with a small-interfering RNA (siRNA) targeting survivin mRNA and analyzed for survivin expression, growth rate, and ability to undergo spontaneous and drug (cisplatin, doxorubicin)-induced apoptosis. RESULTS: Survivin expression was observed in 29 (91%) surgical MPM specimens, whereas the positivity rate for the other IAPs ranged from 69% to 100%. Transfection of MPM cells with the survivin siRNA induced a marked inhibition of survivin protein expression, a time-dependent decline in cell growth and an enhanced rate of spontaneous and drug-induced apoptosis, with a concomitant increase in the catalytic activity of caspase-9. CONCLUSION: Our results show for the first time that survivin, as well as other IAPs, is largely expressed in clinical MPMs and suggest that strategies aimed at down-regulating survivin may provide a novel approach for the treatment of the malignancy.
BACKGROUND: The biology of malignant peritoneal mesothelioma (MPM) is largely unknown. In the present study, we assessed the expression of survivin and other members of the inhibitors of apoptosis proteins (IAP) family (IAP-1, IAP-2 and X-IAP) in a series of 32 MPM surgical specimens and investigated the effects of survivin knockdown in an established MPM cell line. METHODS: Expression of different IAPs was measured by immunohistochemistry. MPM cells were transfected with a small-interfering RNA (siRNA) targeting survivin mRNA and analyzed for survivin expression, growth rate, and ability to undergo spontaneous and drug (cisplatin, doxorubicin)-induced apoptosis. RESULTS: Survivin expression was observed in 29 (91%) surgical MPM specimens, whereas the positivity rate for the other IAPs ranged from 69% to 100%. Transfection of MPM cells with the survivin siRNA induced a marked inhibition of survivin protein expression, a time-dependent decline in cell growth and an enhanced rate of spontaneous and drug-induced apoptosis, with a concomitant increase in the catalytic activity of caspase-9. CONCLUSION: Our results show for the first time that survivin, as well as other IAPs, is largely expressed in clinical MPMs and suggest that strategies aimed at down-regulating survivin may provide a novel approach for the treatment of the malignancy.
Authors: Pietro Bertino; Maddalena Panigada; Elisa Soprana; Valentina Bianchi; Sabrina Bertilaccio; Francesca Sanvito; Aaron H Rose; Haining Yang; Giovanni Gaudino; Peter R Hoffmann; Antonio Siccardi; Michele Carbone Journal: Int J Cancer Date: 2013-02-25 Impact factor: 7.396
Authors: Ilda D'Annessa; Sara Sattin; Jiahui Tao; Marzia Pennati; Carlos Sànchez-Martìn; Elisabetta Moroni; Andrea Rasola; Nadia Zaffaroni; David A Agard; Anna Bernardi; Giorgio Colombo Journal: Chemistry Date: 2017-03-22 Impact factor: 5.236
Authors: Chun Hei Antonio Cheung; Xueying Sun; Jagat R Kanwar; Ji-Zhong Bai; Liting Cheng; Geoffrey W Krissansen Journal: Cancer Cell Int Date: 2010-10-01 Impact factor: 5.722
Authors: Alfonso Baldi; Maria Teresa Piccolo; Maria Rosaria Boccellino; Aldo Donizetti; Irene Cardillo; Raffaele La Porta; Lucio Quagliuolo; Enrico P Spugnini; Francesca Cordero; Gennaro Citro; Massimo Menegozzo; Raffaele A Calogero; Stefania Crispi Journal: PLoS One Date: 2011-08-17 Impact factor: 3.240
Authors: Sara Sattin; Jiahui Tao; Gerolamo Vettoretti; Elisabetta Moroni; Marzia Pennati; Alessia Lopergolo; Laura Morelli; Antonella Bugatti; Abbey Zuehlke; Mike Moses; Thomas Prince; Toshiki Kijima; Kristin Beebe; Marco Rusnati; Len Neckers; Nadia Zaffaroni; David A Agard; Anna Bernardi; Giorgio Colombo Journal: Chemistry Date: 2015-08-18 Impact factor: 5.236